Advaxis receives $244,479 QTDP credit for ADXS11-001 trial

Download PDF Copy

Nov 12 2010

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company's lead immunotherapeutic construct totaling $244,479.

“This non-dilutive funding will support our on-going phase II clinical trials in cervical cancer”

"This non-dilutive funding will support our on-going phase II clinical trials in cervical cancer," said Advaxis Chairman/CEO Thomas A. Moore.

Source: Advaxis, Inc

Posted in: Drug Trial News | Medical Condition News

Tags: Biotechnology, Cancer, Cervical Cancer, Immunotherapy, Listeria

Comments (0)

Download PDF Copy

Suggested Reading

Breakthrough reveals how DNA and RNA epigenetics work together to control genes

Breakthrough reveals how DNA and RNA epigenetics work together to control genes

Protein CD74 could predict immunotherapy response in bowel cancer

Protein CD74 could predict immunotherapy response in bowel cancer

Meet Wanda: The AI-generated influencer spreading cancer prevention messages

Meet Wanda: The AI-generated influencer spreading cancer prevention messages

Study unravels the links between obesity and cancer

Study unravels the links between obesity and cancer

New clinical trial aims to extend survival for bile duct cancer patients

New clinical trial aims to extend survival for bile duct cancer patients

Drug in breast cancer trials shows potential for treating blood cancers

Drug in breast cancer trials shows potential for treating blood cancers

PFAS in US water linked to increased cancer risk

PFAS in US water linked to increased cancer risk

Scientists discover how specific protein regions contribute to breast cancer

Scientists discover how specific protein regions contribute to breast cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

PIN1 protein found to be a significant driver of bladder cancer